I see potentially multiple licencing of ZEN-3694 with multiple royalties for multiple indications in collaborations with multiple pharma.

And this needs Zenith to trade on the open market, not just on the OTC. The stock needs to be liquid for the shareholders to trade on the open market.

However, the first home run for ZEN-3694 in collaboration with a BP, management may decide to sell off the epigenetic drug. What they will do with the cash is another story.

Koo...(IMO)